130525-58-5Relevant articles and documents
Catalytic asymmetric anti-selective nitroaldol reaction en Route to Zanamivir
Nitabaru, Tatsuya,Kumagai, Naoya,Shibasaki, Masakatsu
, p. 1644 - 1647 (2012)
Battling the flu: Zanamivir (Relenza) is widely prescribed as an anti-influenza drug. It contains a vicinal amino alcohol, which is in an anti orientation, and is readily accessed by an anti-selective catalytic asymmetric nitroaldol (Henry) reaction promoted by a heterobimetallic complex (see scheme; PMB=p-methoxybenzyl). Additional synthetic manipulation of the nitroaldol product allowed the enantioselective synthesis of zanamivir. Copyright
SMALL MOLECULE LIGAND-TARGETED DRUG CONJUGATES FOR ANTI-INFLUENZA CHEMOTHERAPY AND IMMUNOTHERAPY
-
Page/Page column 20, (2020/02/16)
Disclosed herein is a small molecule targeted drug conjugate for anti-influenza chemotherapy and immunotherapy. The disclosed drug conjugate may form an adaptor to recruit additional CAR T cells or other immune cells for precise elimination of influenza virus-infected cells in a subject. Concurrently administered antibodies or pre-existing immunity in influenza-virus infected subject works well with the targeted conjugate to eliminate virus infected cells, saving valuable time for rescuing late stage patients.
Synthesis of novel pentacyclic triterpene-Neu5Ac2en derivatives and investigation of their: In vitro anti-influenza entry activity
Shi, Yongying,Si, Longlong,Han, Xu,Fan, Zibo,Wang, Shouxin,Li, Man,Sun, Jiaqi,Zhang, Yongmin,Zhou, Demin,Xiao, Sulong
, p. 1531 - 1541 (2017/07/25)
Sialic acid derivatives, analogs, and their conjugates are important pharmacophores. Modification of the C-4 hydroxyl group of sialic acid can lead to derivatives, such as zanamivir, with potent anti-influenza activities. Herein, we described the synthesis of C-4-modified sialic acid derivatives via conjugation with naturally derived pentacyclic triterpenes, which are active ingredients of traditional Chinese medicine, and the evaluation of their in vitro anti-influenza virus activity in MDCK cells. Interestingly, a set of configurational isomers was obtained during the de-O-acetylation reaction of two pentacyclic triterpene-sialic acid conjugates under Zemplén conditions, and a mechanism was proposed. Owing to the attachment of the Neu5Ac2en moiety, all synthesized conjugates displayed lower hydrophobicity than their parent compounds. In comparison with ursane- and lupane-type triterpenes, oleanane-type triterpene-functionalized Neu5Ac2en conjugates were most promising. The insertion of a (1,2,3-triazol-4-yl)-methyl between the amide bond and Neu5Ac2en caused a substantial decrease in activity. Compound 15a exhibited the highest inhibitory activity (IC50 = 8.3 μM) and selectivity index (SI = 22.7). Further studies involving hemagglutination inhibition and neuraminidase inhibition suggested that compound 15a inhibited virus-induced hemagglutination with no effect on the enzymatic activity of neuraminidase, indicating that the antiviral activity appeared to be mediated via interaction with hemagglutinin at the initial stage of viral infection.
Neuraminidase inhibitor and preparation method and in the preparation of anti-influenza virus application of the medicament (by machine translation)
-
Paragraph 0061; 0062, (2016/10/27)
The invention discloses neuraminidase inhibitor and preparation method and in the preparation of anti-influenza virus application of the medicament. In the general formula (I) - (III) shown in any one of the compound or its pharmaceutically acceptable salt, hydrate, solvate, polymorphic, tautomeric, or prodrug thereof, . Pharmaceutical composition, which comprises at least one of the following: the above-mentioned compound, its pharmaceutically acceptable salt thereof, hydrate thereof, solvate thereof, its amine, the tautomers, prodrugs thereof. Compound or its pharmaceutically acceptable salt, hydrate, solvate, polymorphic, tautomeric, or prodrug thereof in the preparation of anti-influenza virus application of the medicament. Through measuring the compound of the invention with a certain inhibition of influenza virus activity, is expected to be used in preparation of anti-influenza virus drugs. (by machine translation)
